JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Occupancy, Spare Receptors, and the Varieties of Antagonism

Why does maximum effect sometimes arrive before every receptor is filled? And why can one blocker be out-shouted by a bigger dose while another cannot? Occupancy theory answers both.

Occupancy: how full are the receptors?

Receptor occupancy is simply the fraction of a tissue's receptors that have a drug bound at any moment. It rises smoothly with dose, and at a concentration equal to the Kd, occupancy is exactly 50%. The naïve assumption is that response should track occupancy one-for-one: fill 50% of receptors, get 50% of the effect. Often that is roughly true — but not always, and the exception is illuminating.

Spare receptors: a safety margin built in

In many tissues, an agonist reaches its full Emax while occupying only a *fraction* of the receptors — sometimes as little as 1–5%. The leftover, unneeded receptors are the receptor reserve, or spare receptors. They are not a manufacturing mistake; they are a feature. Because the signal saturates downstream before the receptors do, the system responds quickly and reliably even when the messenger is scarce.

Spare receptors have a sharp consequence: the dose for half-maximal *response* (the functional EC50) can sit at a lower concentration than the Kd for half-maximal *occupancy*. In other words, a receptor reserve makes an agonist look more potent than its raw binding affinity alone would predict.

Two ways to block: competitive vs non-competitive

An antagonist reduces an agonist's effect, but *how* it does so splits into two distinct stories. In competitive antagonism, the blocker binds the same site as the agonist, and the two compete. Crucially, this is a tug-of-war you can win with numbers: pile on more agonist and you out-compete the blocker, eventually reaching the same Emax as before. The cost is that you need more agonist — the dose–response curve shifts right (apparent potency drops) but its height is preserved. This is *surmountable* block.

In non-competitive antagonism, the blocker either binds irreversibly or grabs a different site, so heaping on agonist cannot dislodge it. Once enough receptors are taken out of play — including any spare ones — the ceiling drops: the Emax falls and no extra agonist can restore it. This is *insurmountable* block.

Competitive antagonist (same site, reversible):
  curve shifts RIGHT  |  Emax UNCHANGED  |  surmountable by more agonist

Non-competitive antagonist (different site or irreversible):
  Emax DROPS          |  cannot be overcome  |  insurmountable

Memory hook:
  Right-shift, same ceiling  = competitive
  Lower ceiling              = non-competitive
The curve tells you which kind of antagonist you are dealing with.